

No infection recurrence when using CERAMENT® G in infected hip implant management

BONESUPPORT™, a leading company in orthobiologics for the management of bone injuries, today announces positive results from a clinical study demonstrating significantly improved patient-reported outcomes for CERAMENT® G in single-stage revision surgery for patients suffering from periprosthetic joint infection (PJI) of the hip. The top-line results were presented at the European Bone and Joint Infection Society (EBJIS) annual meeting, 11-13 September 2025.

The prospective clinical study conducted at Charité – Universitätsmedizin Berlin, involved twenty patients with confirmed PJI of the hip. The procedure included implant removal, debridement (removal of infected tissue), and defect augmentation using CERAMENT G, followed by cementless revision arthroplasty in a single stage procedure. None of the patients experienced a re-infection during the 24-month follow-up period. Significant improvements were observed in patient-reported outcomes eg. the Harris Hip Score, EQ-5D-5L and Pain Visual Analogue Scale (VAS).

"Periprosthetic joint infections are among the most challenging complications in orthopedic surgery. Despite our best efforts, reinfection and defect reconstruction remain a significant challenge. However, innovative solutions like the gentamicin-eluting bone graft substitute CERAMENT G offer a promising new tool for effectively treating patients with single-stage revision in hip surgery," said Dr. Med. Sebastian Meller.

According to the German Arthroplasty Registry (Endoprothesenregister Deutschland) the risk of reinfection is 30% within two years following hip revision surgery. The current standard of care remains a two-stage procedure, where the infection is treated in a primary surgery and the new prosthesis is implanted in a second surgery up to eight weeks later.

The study (CeraHip) is expected to be published during the autumn.

For more information contact:

BONESUPPORT AB
Torbjörn Sköld, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform **CERAMENT**. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 899 million in 2024. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are **registered trademarks** of BONESUPPORT AB.

Attachments

No infection recurrence when using CERAMENT® G in infected hip implant management